WaveMan
WaveMan · Company
INBX · Inhibrx Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

INBX Inhibrx Biosciences (INBX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0002007919
Quote by TradingView
Cluster · 3 insidersC-suite buying · 1Form 144 · 5
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
107
13F, latest reported quarter

What the filings say about INBX

Insiders, 180 days
+$6.1M net bought
3 buyers · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$279.0K
5 notices

Inhibrx Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Inhibrx Biosciences, Inc. insiders bought a net $6.1M of stock across 112 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Lappe Mark
Chief Executive Officer
BUY
2026-10-14 SEC
2,470
$207.7K
+3.2%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (21 buys, 14 sales), the last on Sep 28, 2026.
  • +0.3% median (+0.7% mean) 90-day return after 10 previous buys.
  • The trade is 0.3% of the 743,018 shares held after it.
  • 1 other insider bought within 30 days.
  • 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lappe Mark bought about $207.7K of INBX on Oct 14, 2026; 1 other insider bought within 30 days and 107 funds added in the latest 13F quarter.
Lappe Mark
Chief Executive Officer
BUY
2026-10-14 SEC
2,470
$209.9K
+3.2%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (21 buys, 14 sales), the last on Sep 28, 2026.
  • +0.3% median (+0.7% mean) 90-day return after 10 previous buys.
  • The trade is 0.3% of the 745,488 shares held after it.
  • 1 other insider bought within 30 days.
  • 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lappe Mark bought about $209.9K of INBX on Oct 14, 2026; 1 other insider bought within 30 days and 107 funds added in the latest 13F quarter.
Lappe Mark
Chief Executive Officer
BUY
2026-10-14 SEC
100
$8.6K
+3.2%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (21 buys, 14 sales), the last on Sep 28, 2026.
  • +0.3% median (+0.7% mean) 90-day return after 10 previous buys.
  • The trade is 0.0% of the 745,588 shares held after it.
  • 1 other insider bought within 30 days.
  • 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lappe Mark bought about $8.6K of INBX on Oct 14, 2026; 1 other insider bought within 30 days and 107 funds added in the latest 13F quarter.
Lappe Mark
Chief Executive Officer
BUY
2026-10-14 SEC
2,449
$205.9K
+3.2%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (21 buys, 14 sales), the last on Sep 28, 2026.
  • +0.3% median (+0.7% mean) 90-day return after 10 previous buys.
  • The trade is 1.5% of the 167,449 shares held after it.
  • 1 other insider bought within 30 days.
  • 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lappe Mark bought about $205.9K of INBX on Oct 14, 2026; 1 other insider bought within 30 days and 107 funds added in the latest 13F quarter.
Lappe Mark
Chief Executive Officer
BUY
2026-10-14 SEC
2,451
$208.3K
+3.2%
Context
  • 35 earlier Form 4 trades (code P or S) here by this insider (21 buys, 14 sales), the last on Sep 28, 2026.
  • +0.3% median (+0.7% mean) 90-day return after 10 previous buys.
  • The trade is 1.4% of the 169,900 shares held after it.
  • 1 other insider bought within 30 days.
  • 107 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lappe Mark bought about $208.3K of INBX on Oct 14, 2026; 1 other insider bought within 30 days and 107 funds added in the latest 13F quarter.
112 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 107 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$6.1M over 180 days
+$6.1M over 90 days
more than 94% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
107 funds bought in last quarter
more than 71% of Pharma & Biotech
Revenue
+550.0% year over year
more than 93% of Pharma & Biotech
Margin
-10773.5% net margin
below 99% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
40.0% of the float short (float per yahoo 2026-10-26) · 11.8 days to cover · settled 2026-09-30
more than 97% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 insiders bought a net $6.1M while the stock fell 28% over six months, but 5 Form 144 notices ($279.0K) are queued to sell.
What changed in the last 30 days
Oct 14Chief Executive Officer Lappe Mark bought $1.8M (9 trades, Sep 25 to Oct 14)

Watch INBX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+196.3%12M
-10%+110%+230%+350%2025-102025-122026-022026-042026-062026-082026-10 2026-09-08 · Lappe Mark bought $1.1M2026-09-08 · Lappe Mark bought $664.7K2026-09-08 · Lappe Mark bought $585.3K2026-09-08 · Kayyem Jon Faiz bought $567.6K2026-09-16 · Kayyem Jon Faiz bought $500.0K2026-09-23 · Kayyem Jon Faiz bought $500.0K2026-09-25 · Lappe Mark bought $328.6K2026-09-28 · Lappe Mark bought $305.1K2026-09-08 · FORSYTH DOUGLAS bought $286.6K2026-09-25 · Lappe Mark bought $216.7K2026-10-14 · Lappe Mark bought $209.9K2026-10-14 · Lappe Mark bought $208.3K2026-10-14 · Lappe Mark bought $207.7K2026-10-14 · Lappe Mark bought $205.9K2026-09-28 · Lappe Mark bought $148.3K2026-09-08 · Lappe Mark bought $136.4K2026-09-08 · Lappe Mark bought $117.8K2026-09-09 · MANHARD KIMBERLY sold $57.9K2026-09-08 · MANHARD KIMBERLY sold $57.6K2026-09-11 · MANHARD KIMBERLY sold $55.9K2026-09-14 · MANHARD KIMBERLY sold $55.1K2026-09-08 · Lappe Mark bought $54.1K2026-09-15 · MANHARD KIMBERLY sold $52.5K2026-10-14 · Lappe Mark bought $8.6K2026-09-15 · MANHARD KIMBERLY filed to sell $52.5K2026-09-14 · MANHARD KIMBERLY filed to sell $55.1K2026-09-11 · MANHARD KIMBERLY filed to sell $55.9K2026-09-09 · MANHARD KIMBERLY filed to sell $57.9K2026-09-08 · MANHARD KIMBERLY filed to sell $57.6K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns INBX: institutional holders (13F)

13F holdings, latest reported quarter
MORGAN STANLEY
1,308,051 sh
$123.9M
PERCEPTIVE ADVISORS LLC
1,297,763 sh
$123.0M
Sanofi
1,157,926 sh
$109.7M
VIKING GLOBAL INVESTORS LP
1,123,929 sh
$106.5M
HighTower Advisors, LLC
870,551 sh
$82.5M

Congress trades in INBX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

INBX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MANHARD KIMBERLY
Filed 2026-09-15
$52.5K
MANHARD KIMBERLY
Filed 2026-09-14
$55.1K
MANHARD KIMBERLY
Filed 2026-09-11
$55.9K
MANHARD KIMBERLY
Filed 2026-09-09
$57.9K
MANHARD KIMBERLY
Filed 2026-09-08
$57.6K

INBX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
HUSSMAN STRATEGIC MARKET CYCLE FUND
$2.8M position · as of 2026-06-30
0.8%
Tema Oncology ETF
$1.1M position · as of 2026-05-31
0.6%
Virtus Biotech Clinical Trials Etf
$276.6K position · as of 2026-07-31
0.6%
HUSSMAN STRATEGIC ALLOCATION FUND
$142.1K position · as of 2026-06-30
0.6%
First Trust Small Cap Growth AlphaDEX Fund
$6.1M position · as of 2026-07-31
0.5%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$38.0M position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
1
Phase 2
1 active
2
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $6.1M bought by insiders over 180 days, 107 funds added last quarter, $279.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

INBX financials

Revenue growth
+550.0%
XBRL, annual
Net margin
-10773.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$131.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.75x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-1,774%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-75.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-85.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.4B
market value at close 2026-10-23 on 2026-08-07 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-9.6%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$1.3M$200.0K$1.8M
Operating income-$135.0M-$331.4M-$219.2M
Net income-$140.1M$1.7B-$241.4M
EPS (diluted)-9.04112.62-20.48
Operating cash flow-$129.8M-$194.4M-$193.3M
Cash$124.2M$152.6M$277.9M
Long-term debt$100.6M$0$207.0M
SEC XBRL, fiscal years, as known on 2026-10-27

INBX Stock Sonar score 6/7 axes

Find similar shapesCompare

INBX ranks highest on growth (93rd percentile) and insider conviction (91st), and lowest on profitability (21st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
21
Inputs
  • Return on equity-1774% · 2 pct, sector of 545
  • Return on assets-75.4% · 31 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-85.4% · 30 pct, sector of 576
Financial health
56
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.75x · 56 pct, sector of 371
Growth
93
Inputs
  • Revenue growth, YoY+550.0% · 93 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
91
Inputs
  • Net Form 4 buying (codes P and S), 180d$6.1M · 94 pct, sector of 428
  • Insider buyers, 180d3 · 89 pct, sector of 437
Institutional and government
71
Inputs
  • Funds adding, latest quarter107 · 71 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
23
Inputs
  • Short interest, % of float+40.0% · 1 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+11.7% · 44 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

INBX filings, in plain words

Are Inhibrx Biosciences insiders buying or selling INBX?

In the 180 days to 2026-10-27, Inhibrx Biosciences insiders were net buyers, a net $6.1M: $6.3M of purchases and $279.0K of sales reported on Form 4, by 3 buyers and 1 seller.

Are there planned insider sales of INBX?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $279.0K of stock; the latest, by MANHARD KIMBERLY, was filed 2026-09-15.

Read the full summary

In the 180 days to 2026-10-27, Inhibrx Biosciences insiders were net buyers of INBX, a net $6.1M across purchases and sales reported on Form 4 by 3 buyers and 1 seller. Purchases outweighed sales more than tenfold by value. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $279.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies